27 Nov | 2024
We hold the annual meeting of the PROMINENT consortium
Representatives from 18 partner organizations have shared the progress of the project and decided on new actions for the future.
Members from the PROMINENT project have gathered at the Barcelonaβeta Brain Research Center (BBRC), research center of the Pasqual Maragall Foundation, for its second consortium meeting. The event, which took place on 21-22 November, provided an opportunity for attendees from 18 partner organizations to meet, exchange expertise and promote the project.
During its annual meeting, the consortium reviewed the project's progress through 2024, assessing the advancement of its six work packages and determining the objectives for 2025 and subsequent steps.
The speakers also analyzed the implications of the recent decision by the European Medicines Agency (EMA) to recommend the approval of lecanemab, a treatment for early-stage Alzheimer’s disease. Among other interventions, Frank Jessen, from the Cologne University Hospital, offered an overview of the current and upcoming anti-amyloid therapies. Additionally, Sandar Aye, from the Karolinska Institute (KI), expanded on patient eligibility assessment for amyloid-targeting therapies in Alzheimer’s disease.
About PROMINENT
PROMINENT is a collaborative pan-European public-private partnership funded through the Innovative Health Initiative (IHI) for five years. PROMINENT is creating a digital platform for implementing precision medicine in neurodegenerative diseases.
The first application of this platform is to assist clinicians with individualized decision support in the evaluation of patients with suspected cognitive impairment due to a dementia disorder. The goal is to help clinicians make optimal use of emerging technologies to diagnose and treat dementia disorders, such as new blood biomarkers and disease-modifying therapies for Alzheimer’s disease.
